Amgen: Hyperlipidemias trials

The registry lists 18 Hyperlipidemias studies with Amgen as lead sponsor. 0 are open to participants now and 17 have results posted.

Phase 1 2Phase 2 4Phase 3 11No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding StudyCompletedNCT04270760Phase 2Results posted
• Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed DyslipidemiaCompletedNCT02833844Phase 3Results posted
• Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))CompletedNCT02729025Phase 3Results posted
• Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed DyslipidemiaCompletedNCT02662569Phase 3Results posted
• Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of EvolocumabCompletedNCT02275156Phase 1Results posted
• Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal AntibodyCompletedNCT02189837Phase 3Results posted
• Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3CompletedNCT01984424Phase 3Results posted
• Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular RiskCompletedNCT01953328Phase 3Results posted
• Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed DyslipidemiaCompletedNCT01854918Phase 3Results posted
• Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2CompletedNCT01763918Phase 3Results posted
• Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2CompletedNCT01763905Phase 3Results posted
• LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2CompletedNCT01763866Phase 3Results posted
• Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2CompletedNCT01763827Phase 3Results posted
• LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapyCompletedNCT01380730Phase 2Results posted
• Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid LevelsCompletedNCT01375777Phase 2Results posted
• Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant SubjectsCompletedNCT01375764Phase 2Results posted
• Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Evolocumab (AMG 145) in Adults With Hyperlipidemia on Stable Doses of a StatinCompletedNCT01133522Phase 1Results posted
• Chart Review of Repatha® in Subjects With HyperlipidaemiaCompletedNCT02770131